NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Vivatides Therapeutics

Vivatides Therapeutics

Private
Woburn, MassachusettsHealthcare & Life Scienceshttps://www.prnewswire.com/

Last Round

Series A

Apr 10, 2026

Total Funding Raised

$64M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Vivatides Therapeutics is a biotechnology company that develops extrahepatic RNA-targeting therapeutics using a proprietary delivery platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

peptide therapeuticsdrug discoverybiotechnologyoligonucleotide therapeuticssiRNAASOdrug deliverybiopharmapreclinical researchligand conjugationdrug developmenttherapeutic pipelinebiotech startupdrug licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vivatides Therapeutics Comparables

Compare Vivatides Therapeutics with similar companies based on industry and business-model similarity.

Vivatides Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nosis Bio
88%
Rona Therapeutics
79%
Procavea Biotech
78%

Vivatides Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 10, 2026
SeedSep 1, 2025

Key People

Founding team and executive leadership

Alexandra Petrie

PA To CEO

Executive Team

medi kelenkoski

CEO

Executive Team

Virginia Spagnuolo

Principal Chief Executive Officer

Executive Team

Dan Ye

CFO Director Of Business Development

Executive Team

Vivatides Therapeutics Investors

Notable investors and investment history

Vivatides Therapeutics investors
InvestorRounds
HighLight CapitalSeries A
Highlight CapitalSeries A
TF CapitalSeries A
Qiming Venture PartnersSeed, Series A
Apricot CapitalSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 10, 2026

    Raised $54M in Series A funding.

  • Sep 1, 2025

    $10M round led by Apricot Capital

Vivatides Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Vivatides Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Vivatides Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersWoburn, Massachusetts
Employee Range1,113
Year Founded2025
Last FundingApr 10, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.